

# Optimising breast cancer outcomes: Clinical and real-world experience lead to strength in numbers

Join us at the virtual Pfizer  
Oncology Satellite Symposium

## ESMO Breast Cancer Virtual Meeting

- 5 MINUTES** What can real-world evidence do for metastatic breast cancer?  
**Nadia Harbeck, Germany**  
From p-values to patient-centricity: refining our approach to metastatic breast cancer treatment
- 15 MINUTES** **Nadia Harbeck, Germany**
- 25 MINUTES** **Hope S. Rugo, USA**
- 15 MINUTES** Emerging therapies in breast cancer: will more options lead to improved outcomes?  
**Nadia Harbeck, Germany**

## Dear Colleagues,

We are delighted to invite you to the Pfizer Oncology satellite symposium ‘**Optimising breast cancer outcomes: clinical and real-world experience lead to strength in numbers**’.

Please join us via the link on the Pfizer exhibition page, where we will discuss the latest evidence for CDK4/6 inhibitors use across a range of patient profiles, and review how emerging real-world evidence can help optimise outcomes in routine clinical practice. In addition to current practice, we will also consider how emerging therapies and ongoing studies may improve patient outcomes in the future across both metastatic and early breast cancer.

**Professor Nadia Harbeck**  
University of Munich (LMU), Germany

**Professor Hope S. Rugo**  
San Francisco, USA

Join our virtual symposium via the hyperlink on the ‘**satellite invitation**’  
section of the Pfizer virtual exhibition page